A randomized, double-blind clinical study of Nicotinamide Riboside in combination with exercise in older adults with hypertension
Latest Information Update: 26 Apr 2025
At a glance
- Drugs Nicotinamide riboside (Primary)
- Indications Hypertension
- Focus Therapeutic Use
Most Recent Events
- 13 Mar 2025 According to ChromaDex Corporation media release, ChromaDex Corp has changed its name to Niagen Bioscience.
- 07 Jan 2020 New trial record
- 06 Jan 2020 According to a ChromaDex media release, Robert Mankowski, PhD, Department of Aging and Geriatric Research, the University of Florida is the primary investigator of this study.